ATE496126T1 - Mutierte srebp-1c promoteren und deren verwendung - Google Patents

Mutierte srebp-1c promoteren und deren verwendung

Info

Publication number
ATE496126T1
ATE496126T1 AT04712761T AT04712761T ATE496126T1 AT E496126 T1 ATE496126 T1 AT E496126T1 AT 04712761 T AT04712761 T AT 04712761T AT 04712761 T AT04712761 T AT 04712761T AT E496126 T1 ATE496126 T1 AT E496126T1
Authority
AT
Austria
Prior art keywords
srebp
mutated
promoters
metabolic disorder
inactivated
Prior art date
Application number
AT04712761T
Other languages
English (en)
Inventor
Yoshihiko Nishio
Hiroshi Maegawa
Atsunori Kashiwagi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE496126T1 publication Critical patent/ATE496126T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0362Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04712761T 2003-02-20 2004-02-19 Mutierte srebp-1c promoteren und deren verwendung ATE496126T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003043398 2003-02-20
JP2003160856 2003-06-05
PCT/JP2004/001924 WO2004074475A1 (ja) 2003-02-20 2004-02-19 転写制御シスエレメント及びそれに特異的に結合する転写調節因子並びにそれらの用途

Publications (1)

Publication Number Publication Date
ATE496126T1 true ATE496126T1 (de) 2011-02-15

Family

ID=32911421

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04712761T ATE496126T1 (de) 2003-02-20 2004-02-19 Mutierte srebp-1c promoteren und deren verwendung

Country Status (5)

Country Link
US (1) US20070032643A1 (de)
EP (1) EP1600507B1 (de)
AT (1) ATE496126T1 (de)
DE (1) DE602004031088D1 (de)
WO (1) WO2004074475A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0304860A (pt) * 2002-11-11 2004-08-31 Ajinomoto Kk Método para produzir uma substância alvo pela utilização de uma-bactéria pertencente ao gênero escherichia
CN104946579A (zh) * 2015-07-03 2015-09-30 浙江大学 一种金华猪乳腺上皮细胞系的培养方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224515A1 (en) * 2002-06-04 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of sterol regulatory element-binding protein-1 expression

Also Published As

Publication number Publication date
DE602004031088D1 (de) 2011-03-03
WO2004074475A1 (ja) 2004-09-02
EP1600507A1 (de) 2005-11-30
US20070032643A1 (en) 2007-02-08
EP1600507B1 (de) 2011-01-19
EP1600507A4 (de) 2006-07-19

Similar Documents

Publication Publication Date Title
EP3992209A4 (de) Cldn18.2-antikörper und verwendung davon
EP3978528A4 (de) Interleukin-4 -rezeptor-antikörper und dessen verwendung
EP3996077A4 (de) Anzeigetafel und ansteuerungsverfahren dafür sowie anzeigevorrichtung
BRPI0507808A (pt) métodos de modular a atividade de citocina; reagentes relacionados
ATE541859T1 (de) Humane anti-interferon-gamma-antikörper und verfahren zu ihrer verwendung
FI20045040A0 (fi) Informaationhallintajärjestelmä työvirtojen hallitsemiseksi
ATE467121T1 (de) Gasüberwachungssystem und seitenstromgasmesssystem, das zur kommunikation mit einem hauptstromgasmesssystem ausgeführt ist
ATE424724T1 (de) Verwendung von n-arylhydrazinderivaten für die bekämpfung von schädlingen in und an tieren
ATE372998T1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
EP3996260A4 (de) Antriebseinheit und fahrzeug
EP3950720A4 (de) Fusionsprotein und verwendung davon
FI20050263A0 (fi) Hissiryhmä ja menetelmä hissiryhmän ohjaamiseksi
DE602006019119D1 (de) Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin
ATE496126T1 (de) Mutierte srebp-1c promoteren und deren verwendung
DE602004021214D1 (de) Regelstrecke mit Kompensation von Störgrössen
CY1110418T1 (el) Αναστολη της αλληλεπιδρασης μεταξυ οξειδωμενων πρωτεϊνων και cd36 ή ο μηχανισμος δρασης τους
EP4071171C0 (de) Anti-tm4sf4-antikörper und verwendung davon
DE502005009098D1 (de) 2-(pyridin-2-yl)-pyrimidine und ihre verwendung zur bekämpfung von schadpilzen
DE60322052D1 (de) N-acylaminoacetonitril-derivate und ihre verwendung zur kontrolle von parasiten
EP3859441A4 (de) Anzeigetafel, verfahren zu ihrer ansteuerung und anzeigevorrichtung
EP3642226A4 (de) Neuartige nukleinsäuremoleküle und deren verwendung in der therapie
FI20040838A0 (fi) Vaihtosuuntaajan pulssinleveysmodulaattorin ohjaus
DE602006016048D1 (de) Stromquellensystem und zugehöriges steuerungsverfahren
UY29717A1 (es) Un método para controlar malezas
ATE372990T1 (de) Oxazolderivat und deren verwendung als insulinsensibilisatoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties